In Nature communications ; h5-index 260.0
Non-invasive biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are urgently needed. Such biomarkers can improve the safety of analytic treatment interruption (ATI) and provide mechanistic insights into the host pathways involved in post-ART HIV control. Here we report plasma glycomic and metabolic signatures of time-to-viral-rebound and probability-of-viral-remission using samples from two independent cohorts. These samples include a large number of post-treatment controllers, a rare population demonstrating sustained virologic suppression after ART-cessation. These signatures remain significant after adjusting for key demographic and clinical confounders. We also report mechanistic links between some of these biomarkers and HIV latency reactivation and/or myeloid inflammation in vitro. Finally, machine learning algorithms, based on selected sets of these biomarkers, predict time-to-viral-rebound with 74% capacity and probability-of-viral-remission with 97.5% capacity. In summary, we report non-invasive plasma biomarkers, with potential functional significance, that predict both the duration and probability of HIV remission after treatment interruption.
Giron Leila B, Palmer Clovis S, Liu Qin, Yin Xiangfan, Papasavvas Emmanouil, Sharaf Radwa, Etemad Behzad, Damra Mohammad, Goldman Aaron R, Tang Hsin-Yao, Johnston Rowena, Mounzer Karam, Kostman Jay R, Tebas Pablo, Landay Alan, Montaner Luis J, Jacobson Jeffrey M, Li Jonathan Z, Abdel-Mohsen Mohamed